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Background/aim: The aim of this study was to establish the relationship between the needle biopsy and the pathology result after radical
prostatectomy administrated for prostate cancer.
Materials and methods: We retrospectively analyzed 67 patients who had undergone radical prostatectomy from 2016 to 2019. All surgeries and all biopsies were performed in the third author’s urology department. Samples were collected through 12-core biopsy under
local anesthesia. All specimens were studied in the pathology department of the third author’s center. The results evaluated were needle
biopsies’ Gleason scores and prostatectomy specimens’ Gleason scores.
Results: Inclusion criteria were not having any neo-adjuvant treatment and being treated with surgery after needle biopsy. Gleason
scores obtained from needle biopsies and prostatectomy specimens were evaluated. The comparison revealed that 39% of the tumors
were undergraded, 7% were overgraded, and 54% had exact scoring in needle biopsies and prostatectomy specimens according to the
detailed Gleason scoring as primary and secondary metrics. The patients were grouped into five categories according to the ISUP 2014
prostate cancer grading system. The relationship was strong with 64% of results staying in the same group after the operation; nevertheless, the correlation remained weak based on the kappa coefficient.
Conclusion: The information obtained from the needle biopsy is not a strong herald of the pathological result. Urologists should have
awareness of this restraint when utilizing the needle biopsy’s Gleason score in decision making and treatment planning.
Key words: Accuracy, biopsy pathology, correlation, prostate cancer, prostatectomy pathology

1. Introduction
Clinical staging of the prostate cancer is essential in
starting a therapy plan [1]. Transrectal ultrasound
(TRUS)-guided prostate biopsy is a standard procedure
for predicting postoperative pathological grade in many
centers [2]. Clinical grades refer to prostate biopsy and are
critical in patients who are candidates for radiotherapy or
watchful waiting because these stages guide prognosis and
treatment [3].
The accuracy of needle biopsy is inconclusive [4,5].
Magnetic resonance imaging (MRI)-guided prostate
biopsy including MRI/ultrasound fusion biopsy is rapidly
increasing with good accuracy [6,7]. On the other hand,
repeat biopsy procedure and saturation biopsy methods
can empower urologists to improve the accuracy [8,9].
Nevertheless, urologists still rely on 12-core needle
biopsies because other methods are rare, require more
personnel, and are more invasive. Therefore, we evaluated

the correlation between the Gleason scores on biopsies
and prostatectomy specimens in 67 patients who were
diagnosed with prostate adenocarcinoma, had no neoadjuvant treatment or radiotherapy, and had undergone
radical prostatectomy (RP).
2. Materials and methods
The retrospective study was conducted in Erciyes
University, Faculty of Medicine, Department of Urology.
Sixty-seven patients who underwent RP for prostate
adenocarcinoma in our center between 2016 and 2019
were enrolled. The patients’ files, charts, and computerized
data were collected, and the pathology results of needle
biopsies and prostatectomy specimens, ages, and PSA
levels before biopsies were noted. Pathology results were
summarized including Gleason score as the primary and
secondary grading in needle biopsies and prostatectomy
specimens, border extension, and seminal vesicle invasion
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in prostatectomy specimen results as well. Patients were
subjected to clinical tumor node metastasis classification
for staging (Table 1). T-staging is mainly based on digital
rectal examination (DRE), but transrectal ultrasonography
(TRUS) or multiparametric MRI is also considered if
performed. N-staging was mostly done with computed
tomography (CT) and MRI. M-staging was mostly done
with bone scan.
Patients were defined as localized and locally advanced
prostate cancer according to the PSA level, Gleason
score, and clinical staging. For surgical treatment, a
life expectancy of at least 10 years is required. Active
surveillance, radiotherapy, and radical prostatectomy
options are offered to the patients in the localized group.
Radiotherapy and radical prostatectomy options are
offered to patients in the locally advanced group (Table
2). The patients in our study are patients who proceeded
according to this scheme and finally decided and applied
radical prostatectomy. A senior surgeon managed all the

RPs and another experienced surgeon helped the senior
surgeon.
All specimens were studied in our hospital’s own
pathology department by randomly assigned pathologists.
Clinical information (e.g., age, DRE, PSA) was also included.
A positive surgical margin was defined as the presence of
cancerous tissue in contact with the inked surface of the
prostatectomy specimen. Healthy tissue margins were
considered negative margins. Some of the biopsy reports
where the tumor was graded as good, moderate, or poor
differentiation did not contain Gleason scores; thus, these
documents were excluded from the study. No patient
received radiotherapy or hormone therapy before RP. The
Gleason grades were compared separately in biopsy and
pathology groups as primary and secondary. The sums of
Gleason scores were compared in biopsy and pathology
groups. Grade groups in which the score totals correspond
to International Society of Urological Pathology (ISUP)
were also compared before and after RP (Table 3) [10].

Table 1. Clinical tumor node metastasis classification of prostate cancer.
T- primary tumor
TX

Primary tumor cannot be assessed

T0

No evidence of primary tumor

T1

Tumor that is palpable and confined within the prostate

T2

T3

T4

T1a

Tumor incidental histological finding in 5% or less of tissue resected

T1b

Tumor incidental histological finding in more than 5% of tissue resected

T1c

Tumor identified by needle biopsy (e.g., because of elevated PSA)

Tumor that is palpable and confined within the prostate
T2a

Tumor involves one half of one lobe or less

T2b

Tumor involves more than half of one lobe, but not both lobes

T2c

Tumor involves both lobes

Tumor extends through the prostatic capsule
T3a

Extracapsular extension (unilateral or bilateral)

T3b

Tumor invades seminal vesicle(s)

Tumor is fixed or invades adjacent structures other than seminal vesicles: external sphincter, rectum, levator muscles, and/or
pelvic wall

N – regional (pelvic) lymph nodes
NX

Regional lymph nodes cannot be assessed

N1

No regional lymph node metastasis

N2

Regional lymph node metastasis

M - distant metastasis
M0

No distant metastasis

M1

Distant metastasis
M1a

Non-regional lymph node(s)

M1b

Bone(s)

M1c

Other sites(s)
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Table 2. Risk groups for biochemical recurrence of localized and locally advanced prostate cancer.
Definition
Low-risk

Intermediate-risk

High-risk

PSA < 10 ng/mL

PSA 10 - 20 ng/mL

PSA > 20 g/mL

any PSA

and ISUP grade 1

or ISUP grade 2–3

or ISUP grade 4–5

any ISUP grade

and cT1 - T2a

or cT2b

or cT2c

cT3–4 or cN1

Localized

Locally advanced

Table 3. ISUP 2014 grades.

Table 5. Patients’ descriptives.

Gleason score

ISUP grade

2–6

1

7 (3 + 4)

2

7 (4 + 3)

3

8 (4 + 4 or 3 + 5 or 5 + 3)

4

9–10

5

Table 4. Kappa coefficient interpretation.
Value of κ

Strength of agreement

0

Chance agreement

<0.4

Poor agreement

0.4–0.75

Good agreement

<0.75

Excellent agreement

IBM SPSS version 22.0 (IBM Corp. Armonk, NY, USA)
was used for statistical analysis of the datasets. Cohen’s
kappa (κ) analysis was used to determine the agreement
between biopsy and pathology results. The strength of the
agreement was evaluated according to κ coefficient (Table
4). In all tests, the statistical significance level was set at
0.05.
3. Results
The mean age of the patients was 60.4 ± 5.7 years (range:
46–78). The mean of the PSA levels was 11.5 ± 7.8 ng/mL
(range: 4–54). The mean Gleason score was 6.25 ± 0.97
(range: 4–9) on needle biopsies and 6.69 ± 1.17 (range:
4–10) on pathology specimens (Table 5).
The biopsy results were described as primary and
secondary Gleason grades and were compared to the
results of the prostatectomy specimens; Gleason grades on
biopsies remained identical in 54%, were undergraded in
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n = 67

Gleason score on
Age

PSA level

Biopsy

Specimen

mean

60.4

11.5

6.25

6.69

sd ±

5.7

7.8

0.97

1.17

range

46–78

4–54

4–9

4–10

7%, and overgraded in 39% on prostatectomy specimens.
The κ coefficient was calculated as 0.37 in statistical
correlation tests (p < 0.01). The primary and secondary
Gleason grades of the biopsy revealed a poor prediction of
prostatectomy specimens’ primary and secondary Gleason
grades.
The biopsy results were defined as the individual
Gleason scores and confirmed with prostatectomy
specimens’ results. The total Gleason scores of biopsies
remained the same in 55%, were undergraded in 9%,
and overgraded in 36% on prostatectomy specimens. The
κ coefficient was 0.34 in statistical correlation tests (p <
0.01). The individual Gleason score of the biopsy showed
a poor prediction of prostatectomy specimens’ individual
Gleason scores.
The results were divided into groups according to ISUP
2014 prostate cancer grading system. The biopsies were
compared with the groups of prostatectomy specimens,
and the groups of biopsies stayed the same in 64%,
undergraded in 8%, and overgraded in 28% on groups
of prostatectomy specimens. Although the number that
remained identical increased, this was not reflected in the
accuracy test. The κ coefficient was computed as 0.39 in
statistical correlation testing (p < 0.01). The biopsy groups
in binary groups had a poor correlation with prostatectomy
specimens (Table 6).
4. Discussion
Prostate cancer ranks fourth among cancers worldwide
[11]. DRE is a simple and established tool to diagnose
prostate cancer [12]. Current methods can provide a cure
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Table 6. Overall correlation for ISUP grades in the biopsy and prostatectomy specimens.
(Total = 67)

ISUP grade on prostatectomy specimen

ISUP grade on biopsy

Grade 1
(n = 34)

Grade 2
(n = 15)

Grade 3
(n = 8)

Grade 4
(n = 3)

Grade 5
(n = 7)

Grade 1 (n = 44)

30

8

3

2

1

Grade 2 (n = 13)

3

7

1

0

2

Grade 3 (n = 5)

1

0

3

0

1

Grade 4 (n = 3)

0

0

1

1

1

Grade 2 (n = 2)

0

0

0

0

2

to suitable patients via radical prostatectomy [13]. Patients
with localized prostate cancer who do not have prostatic
capsule involvement and have no evidence of metastasis
are suitable for radical prostatectomy [14]. However,
radical prostatectomy is not performed in every patient
with localized prostate cancer [15]. Clinical staging is
decisive when planning the treatment of patients with
prostate cancer [16]. Depending on the clinical stage,
watchful waiting or radiation therapy may also be an
alternative [17]. Thus, special efforts have been made for
accurate clinical staging. The most important condition of
correct clinical staging is that the biopsy results show the
pathology results with high accuracy.
The most common mismatch between biopsy and
pathology in the literature is the undergrading of biopsy
[18]. We found that biopsy samples showed undergrading
versus pathology in each evaluation group. In addition, the
prostate biopsy does not have sufficient accuracy, which
is a common issue in the literature [19]. In the literature,
multiparametric prostate MRI and MRI fusion biopsy have
higher kappas than conventional prostate biopsy [20,21]
In the literature, studies reporting a weak correlation
between biopsy and prostatectomy total Gleason scores
are common [22]. We found that the compliance was 55%
with weak correlation when the total Gleason score was
considered. Similarly, the literature shows discrepancy
when the Gleason score was defined as the primary and
secondary points [23]. There was 54% agreement and
weak correlation consistent with the literature. In our
study, the total Gleason scores were classified according
to ISUP 2014 prostate cancer grading system, and the
agreement was 64% with correlation statistics that
showed poor agreement. This result was compatible with
the literature [24]. In detail, in the grade 2 group, 54%
remained identical, 23% were undergraded, and 23% were
overgraded. In grade 3, 60% remained identical, 20% were
undergraded, and 20% were overgraded. With a more
accurate method, about a quarter of these patients could
have been kept under active surveillance and thus could
have been protected from the side effects of the treatment
if only temporarily.

Accuracy and correlation are important in common
malignant disease and staging is important. Our data and the
literature suggest that only conventional biopsy is insufficient
to predict pathology results. In light of this information,
prostate biopsy should not be trusted alone. Considering
that there are as many undergraded results as accurate
results, treatment planning based on these results alone
may not be accurate. We found that prostate biopsy is not so
reliable as to ignore alternative methods. Urologists should
try to compensate for this limitation by using repeat biopsy,
saturation biopsy, and/or MRI-supported biopsy according
to the case history and details.
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